Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction† by Huikuri, Heikki V. et al.
.....................................................................................................................................................................................
.....................................................................................................................................................................................
CLINICAL RESEARCH
Arrhythmia
Prediction of fatal or near-fatal cardiac
arrhythmia events in patients with depressed
left ventricular function after an acute
myocardial infarction†
Heikki V. Huikuri1*, M.J. Pekka Raatikainen1, Rikke Moerch-Joergensen2,
Juha Hartikainen3, Vesa Virtanen4, Jean Boland5, Olli Anttonen6, Nis Hoest7,
Lucas V.A. Boersma8,E i v i n dS .P l a t o u 9,M a r cD .M e s s i e r 10,a n d
Poul-Erik Bloch-Thomsen2 for the Cardiac Arrhythmias and Risk Stratiﬁcation
after Acute Myocardial Infarction (CARISMA) study group
1Department of Internal Medicine, University of Oulu, PO Box 5000 (Kajaanintie 50), 90014 Oulu, Finland;
2Gentofte University Hospital, Copenhagen, Denmark;
3Department of
Internal Medicine, University of Kuopio, Kuopio, Finland;
4Department of Cardiology, University of Tampere, Tampere, Finland;
5Department of Internal Medicine, Hopital Citadelle,
Liege, Belgium;
6Department of Internal Medicine, Pa ¨ija ¨t-Ha ¨me Central Hospital, Lahti, Finland;
7Glostrup Hospital, Copenhagen, Denmark;
8St Antonious Hospital, Nieuwegein,
The Netherlands;
9Department of Cardiology, Center for Arrhythmias, Ulleva ˚l University Hospital, Oslo, Norway; and
10Medtronic Bakken Research Center, Maastricht,
The Netherlands
Received 25 April 2008; revised 30 October 2008; accepted 6 November 2008; online publish-ahead-of-print 20 January 2009
Aims To determine whether risk stratiﬁcation tests can predict serious arrhythmic events after acute myocardial infarction
(AMI) in patients with reduced left ventricular ejection fraction (LVEF   0.40).
Methods
and results
A total of 5869 consecutive patients were screened in 10 European centres, and 312 patients (age 65+11 years)
with a mean LVEF of 31+6% were included in the study. Heart rate variability/turbulence, ambient
arrhythmias, signal-averaged electrocardiogram (SAECG), T-wave alternans, and programmed electrical stimulation
(PES) were performed 6 weeks after AMI. The primary endpoint was ECG-documented ventricular ﬁbrillation or
symptomatic sustained ventricular tachycardia (VT). To document these arrhythmic events, the patients received
an implantable ECG loop-recorder. There were 25 primary endpoints (8.0%) during the follow-up of 2 years. The
strongest predictors of primary endpoint were measures of heart rate variability, e.g. hazard ratio (HR) for
reduced very-low frequency component (,5.7 ln ms
2) adjusted for clinical variables was 7.0 (95% CI: 2.4–20.3,
P , 0.001). Induction of sustained monomorphic VT during PES (adjusted HR ¼ 4.8, 95% CI, 1.7–13.4, P ¼ 0.003)
also predicted the primary endpoint.
Conclusion Fatal or near-fatal arrhythmias can be predicted by many risk stratiﬁcation methods, especially by heart rate variability,
in patients with reduced LVEF after AMI.
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Survivors of an acute myocardial infarction (AMI) who have
impaired left ventricular ejection fraction (LVEF   0.40) are at
high risk of dying suddenly due to cardiac arrhythmias.
1–4Prophy-
lactic implantation of a cardioverter-deﬁbrillator (ICD) has been
shown to reduce all cause mortality among these patients, when
the ICD was implanted late after AMI.
5,6 The beneﬁt is reportedly
less marked in patients who received an ICD early after the acute
event.
3,7 There is, therefore, a need to identify other risk markers
beyond the LVEF for patients who are at risk of sudden arrhythmic
deaths and who could also beneﬁt from implantation of an
ICD early after AMI, a time period which accounts for a large
cumulative number of sudden deaths worldwide.
2
Several non-invasive and invasive risk stratiﬁcation tests are able
to predict all-cause mortality after AMI.
8–14 All-cause mortality,
however, in combination with other endpoints,
8–15 is not con-
sidered a reliable surrogate for life-threatening or fatal arrhythmic
events.
15 Previous observational risk stratiﬁcation studies have not
adequately estimated the need of an ICD in view of such endpoint
limitation and incomplete event documentation.
15 The Cardiac
Arrhythmias and Risk Stratiﬁcation after AMI (CARISMA) trial
was designed to investigate the power of various invasive and non-
invasive risk markers to predict the occurrence of arrhythmias that
could probably be treated by an ICD after AMI. An implantable
ECG loop-recorder was used to document fatal or near-fatal
ventricular tachyarrhythmias as a primary endpoint of the study.
Methods
Study population and protocol
A total of 5869 consecutive patients were screened in the acute phase
of AMI (2–7 days after the event) in 10 European centres between
August 2001 and November 2004. Of these, 1393 (23%) patients
had a LVEF   0.40. After exclusions, 312 patients were included in
the study. The inclusion and exclusion criteria are shown in Table 1
and a ﬂow chart of the study design is shown in Figure 1. A consecutive
series of patients with an ECG and enzyme deﬁned AMI were screened
and patients with a LVEF  0.40, measured 3–5 days post-AMI, were
included in the study. Day 0 was the time when the AMI was diag-
nosed. Major reasons for exclusion from the study among the patients
with a LVEF 0.40 were refusal of the patient or the attending phys-
ician treating the patient for participation in the study (n ¼ 380), the
inability of the patient to participate in the study due to other
serious illness (n ¼ 312), planned coronary bypass graft surgery (n ¼
184) or death (n ¼ 89) before the implantation of a loop-recorder
and/or the risk stratiﬁcation tests. The patients included in the study
received an implantable ECG loop-recorder 5–21 days after AMI to
document arrhythmic events and were followed-up for 24 months
to document arrhythmic events. The patients had clinical visits at
3-month intervals up to 2 years after AMI. The last follow-up was
planned to be at 24 months after AMI. The appropriate ethics
review boards approved the protocol and the study was conducted
in accordance with the Declaration of Helsinki.
Endpoints of the study
The primary endpoint of the study was ECG-documented fatal or
near-fatal cardiac arrhythmia, adjudicated as ‘most probably treatable’
by an ICD according to a consensus of the ﬁve-member endpoint com-
mittee blinded to the test results. This included resuscitated cardiac
arrest due to documented primary arrhythmia, symptomatic sustained
ventricular tachycardia (VT), or documented arrhythmic death. Each
arrhythmia had to be ECG-documented, either by the implanted
loop-recorder, ICD, pacemaker, Holter recording, or telemetry strip.
An arrhythmic event was excluded as a primary endpoint when
considered by any member of the endpoint committee, that it could
not have been successfully treated by an ICD. For example, docu-
mented arrhythmic events did not meet the deﬁnition of the
primary endpoint if they occurred in end-stage chronic heart failure
or during refractory ischaemia. All-cause mortality and cardiac death
were secondary endpoints.
Implantation and programming of the
loop-recorder
An implantable loop-recorder (Reveal Plus, Medtronic Inc.,
Minneapolis, MN, USA) with automatic ECG storage was used to
document the primary endpoint.
16,17 The device was implanted
subcutaneously under local anaesthesia in the left parasternal area
5–21 days after an AMI and programmed automatically to
store tachyarrhythmias at heart rates  125 beat/min that persist
for at least 16 consecutive beats, and to automatically store bradyar-
rhythmias at heart rates  30 beats/min, or asystole for at
least 4.5 s.
16
During follow-up, the memory of the loop-recorder was interro-
gated 6 weeks after implantation and thereafter at 3-month intervals.
................................................................................
Table 1 Inclusion and exclusion criteria of the patients
Inclusion criteria
AMI, veriﬁed by enzyme analyses or elevated troponin and
associated with typical chest pain and/or ECG changes according to
the European Society of Cardiology and American College of
Cardiology consensus documents
LVEF   40%, measured between Days 3 and 21 post-AMI,
preferably before Day 7
Exclusion criteria
Index AMI older than 21 days
Death before the implantation of loop-recorder
Patient unwilling or unable to give written informed consent
Insertable loop-recorder cannot be implanted within 3 weeks after
AMI for any reason except planned pacemaker implantation
NYHA class IV despite appropriate treatment of heart failure
Planned or previous ICD implantation; planned CABG; severe
valvular disease
Participation in a competing clinical trial
Psychologically or physically (due to any other illness) unﬁt for
participation in the study according to the opinion of the
investigator; Patient compliance doubtful
Patients who are geographically or otherwise inaccessible for
follow-up
Pregnancy; life expectancy ,1 year for non-cardiac cause; age
below 18
AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; LVEF,
ejection fraction; ICD, implantable cardioverter-deﬁbrillator; ILR, insertable
loop-recorder.
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according to the amount of false events at each visit. Over the
course of the study, some patients were implanted with other
cardiac devices, such as pacemaker (n ¼ 22, 17 due to intermittent
or permanent II–III degree AV-block, and 5 due to sinus node
disease) or ICDs (n ¼ 57, 2 due to resuscitated cardiac arrest, 10
due to sustained ventricular tachycardia, and 45 due to prophylactic
indications), which were used to document the arrhythmic events as
evidence of primary endpoint. The ICD programming was left at the
discretion of the primary physicians. In order to differentiate
between non-sustained and sustained VT, however, the ICDs were
required to be programmed with no antitachycardia pacing or ICD
shock delivered within the ﬁrst 30 s delay, i.e. with therapy ‘off’
and with monitoring ‘on’ for .76 beats between the cycle lengths
of 480 and 310 ms. In cases with fast VT or ventricular ﬁbrillation
(VF), deﬁned as rates from 194 to 220 bpm and .220 bpm, respect-
ively, the therapy was typically programmed to be delivered after
d e t e c t i o no f1 8i n t e r v a l s .
Description of the methods in risk
stratiﬁcation
Echocardiography
A 2-dimensional echocardiogram was performed twice, 2–5 days after
index AMI, and at 6 weeks post-AMI. The LVEF was measured locally
by the investigators using standard techniques.
18,19
Holter monitoring
All patients underwent a 24 h ambulatory two or three-channel ECG
recording, immediately after the index AMI (between Days 5 and 21)
and at Week 6. The analysis methods of various measures of heart
rate variability/turbulence have been described elsewhere.
18–23 The
following variables were analysed: average heart rate, total number
and frequency of premature ventricular beats, episodes of non-
sustained ventricular tachycardia ( 3 consecutive beats), time and fre-
quency domain measures along with short-term fractal exponent of
heart rate variability, the onset and slope of heart rate turbulence.
Holter recordings were analysed locally by an experienced technician
in each centre, and the heart rate variability/turbulence measures
were analysed centrally at the University of Oulu (Finland) using a
previously described custom-made software.
18–23
Microvolt T-wave alternans
Exercise tests and microvolt T-wave alternans analysis were performed
at 6 weeks post-AMI.
21 Maximal work load, heart rate, blood pressure,
and ST-T changes were analysed from the symptom-limited exercise
ECG. The presence of microvolt T-wave alternans was assessed
using a CH2000 system (Cambridge Heart, Inc., Bedford, MA, USA)
and high-resolution electrodes with standard 12-lead ECG and three
orthogonal (X,Y,Z) ECG lead positions. Initially, the test was
performed using a bicycle exercise protocol.
21 Test results were
deﬁned as positive, negative, or incomplete/indeterminate.
21,24 The
goal of the exercise test was to achieve a target heart rate at least
105 beats/min and to maintain a slowly increasing heart rate
between 105 and 110 beats/min for 2–3 min. The exercise stress
test was then continued as symptom-limited test until exhaustion.
For patients with an incomplete or indeterminate result, the microvolt
T-wave alternans was re-analysed during the electrophysiological study
by relying on atrial or simultaneous ventricular and atrial pacing. Earlier
pilot work describes these pacing methods as well as the concordance
between exercise test and pacing in the analysis of T-wave alternans.
24
The tests were interpreted locally by the investigators and re-analysed
independently by a Cambridge Heart Inc. expert review board blinded
to the outcome. The results are reported both for the exercise TWA
testing and the TWA testing obtained from exerciseþpacing.
Signal-averaged electrocardiogram
Signal-averaged ECGs were performed at 6 weeks post-AMI by devices
capable of measuring averaged high-frequency QRS-complexes.
17,20
Filtered QRS duration .120 ms, the root mean square voltage of
the terminal 40 ms of the ﬁltered QRS complex ,20 mV or the
duration of the terminal portion .38 ms were predeﬁned criteria
for abnormal signal-averaged ECG.
18,21 All signal-averaged ECGs
were analysed locally by the investigators.
Electrophysiological study
A programmed electrical stimulation (PES) was performed 6 weeks
post-AMI during a standard electrophysiological study with up to
three extra stimuli (minimum of 200 ms) and up to two basic drive
cycle lengths (600 and 400 ms) from the right ventricular apex and
outﬂow tract. Induction of sustained monomorphic ventricular
Figure 1 Study Flow Chart. *Major reasons for exclusions
from the study were refusal of the patient or the attending
physician treating the patient for participation in the study
(n ¼ 380), the inability of the patient to participate in the study
due to other serious illness (n ¼ 312), planned coronary bypass
graft surgery (n ¼ 184) or death (n ¼ 89) before the implantation
of a loop-recorder and/or the risk stratiﬁcation tests. AMI, acute
myocardial infarction; EP, electrophysiological; ILR, implantable
loop-recorder; SAECG, signal-averaged electrocardiogram;
TWA, T-wave alternans.
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including ventricular ﬁbrillation and sustained polymorphic ventricular
tachycardia, were analysed separately.
Standard 12-lead electrocardiogram
QT interval, QTc interval, QT dispersion, and QRS duration were ana-
lysed from a standard 12-lead ECG.
18
Statistical analysis
In sample size calculation, the study was designed to have a 90% power
to detect at least a three-fold risk of primary endpoint of any of the risk
variables, assuming that 10–30% of the patients would have abnormal
test results. The rate of primary endpoints was estimated to be 10%
based on prior literature.
Hazard ratios (HR) obtained by the Cox proportional hazard
models were ﬁtted to identify predictors of primary and secondary
endpoints. Analysis were conducted using risk variables as continuous
variables when it was possible. HR were also calculated on dichoto-
mized test variables at thresholds predeﬁned before the study onset,
based on prior experience
18–23 after adjustments for common risk
variables, such as age, prior AMI, history of congestive heart failure,
and diabetes. The time to development of the primary endpoint was
displayed by constructing Kaplan–Meier curves and the signiﬁcance
estimated by a log-rank test. All analyses were performed in SAS
v. 9.1. Two-sided P-values ,0.05 were considered signiﬁcant.
Results
Of the 312 enrolled patients, 25 (8.0%) experienced a primary end-
point during the follow-up. Twelve of these were symptomatic sus-
tained monomorphic VTs, eight were sudden deaths, three aborted
cardiac arrests, and two patients had syncope before termination of
VF by ICD shock. The clinical presentation, type of documented
arrhythmia, and the mode of diagnosing the primary endpoints are
shown in Figure 2. Ten out of the 12 sustained VTs were
documented by the ILR and two by the ICD. Six sudden deaths
were due to VF, four documented by the ILR, and two by ECG
strip obtained by telemetry. Two sudden deaths were preceded
by fast VT, one documented by the ILR, and one by telemetry
strip. Two patients with resuscitated cardiac arrest had VF and
one had fast VT. The arrhythmia was terminated by the external
DC shock among these three patients. Two of these were docu-
mented by the ILR and one occurred during the Holter recording.
VT (n ¼ 3) or VF (n ¼ 4) was documented by the ILR in seven
patients, in whom the documented arrhythmias were not con-
sidered as primary endpoints. Five of these occurred among patients
hospitalized due to terminal heart failure, one occurred in a patient
dying for acute heart failure, and one occurred in a hospitalized
patient with a recurrent AMI associated with frequent VF episodes
not responding to DC shocks and resuscitation attempts.
During the median follow-up of 2.02 years (quartiles from 1.97
to 2.06 years) (mean 1.85+0.5 years), 38 patients (12.2%) died,
with 28 of the deaths (9.0%) classiﬁed as cardiac deaths. None
of the patients with an implanted ICD died suddenly during the
follow-up. Seven patients had died before the 6-week risk stratiﬁ-
cation tests. The characteristics of the whole study cohort are
described in Table 2.
Fractal heart rate variability index measured from Holter record-
ings 1 week post-AMI was a signiﬁcant predictor of primary
endpoint. No other heart rate variability index or LVEF, were able
to predict the primary endpoint when measured very early after
AMI (Table 3). At 6 weeks post-AMI, however, standard deviation
of N–N intervals, very-low frequency and high-frequency power
spectral components, fractal scaling exponent of heart rate variabil-
ity as well as heart rate turbulence slope predicted the primary end-
point, as evidenced by a relatively high AUC values and adjusted HR
of pre-deﬁned dichotomized values (Table 3 and Figure 3). In the
total study cohort, a per-patient LVEF increased from baseline
value of 31+6t o3 5 +10% at 6 weeks (P , 0.001), while the
Figure 2 Clinical presentation, type of documented arrhythmia, and the mode of documentation of primary endpoints. ICD, implantable
cardioverter-deﬁbrillator; ILR, implantable loop-recorder; VT, ventricular tachycardia; VF, ventricular ﬁbrillation.
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endpoint (30+6t o3 2+6%, P ¼ 0.7). However, the HR of LVEF
as a continuous variable at 6 weeks (HR ¼ 0.96, 95% CI: 0.92–
1.006, P ¼ 0.09) or the change of LVEF from baseline to 6 weeks
(HR ¼ 0.95, 95% CI: 0.91–1.00, P ¼ 0.06) did not reach signiﬁcance
as predictors of the primary endpoint.
QRS duration measured from the signal-averaged ECG was a
signiﬁcant predictor of the primary endpoint, as was induction of
sustained monomorphic VT (Table 3). However, when adjusted
to clinical variables, the predictive power of signal-averaged ECG
was only of borderline signiﬁcance (P ¼ 0.04) (Figure 2). Prolonged
QT dispersion also predicted the primary endpoint (Table 3 and
Figure 3). Microvolt T-wave alternans, analysed either from the
exercise test or exerciseþpacing, non-sustained ventricular
tachycardia or frequency of premature beats on Holter and QRS
duration measured from the 12-lead ECG were not signiﬁcant
predictors of the primary endpoint.
All-cause mortality and cardiac death were also predicted by
several heart rate variability measures, QRS-duration, and
maximal exercise capacity but not by PES (Table 3).
Table 4 shows the sensitivity, speciﬁcity, and predictive values of
signiﬁcant predictors of the primary endpoint. These values illus-
trate the relatively high accuracy of some heart rate variability
indexes, especially the very-low frequency spectral component,
as well as inducibility of sustained monomorphic VT in predicting
the primary endpoint. The Kaplan–Meier representation of time
to primary endpoint is shown in Figure 4, stratiﬁed by inducibility
of sustained monomorphic VT or by reduced very-low frequency
spectral component of heart rate variability.
Discussion
The present prospective, multicenter study showed that several
measures of heart rate variability analysed at 6 weeks after AMI
among patients with impaired LVEF are powerful predictors of
the occurrence of ECG-documented fatal or near-fatal arrhythmic
events that could have probably been treated by an ICD. Induction
of monomorphic sustained VT during PES and prolonged QRS dur-
ation measured from SAECG also predicted the arrhythmic events.
Our primary endpoint was distinctly different compared with
previous observational risk stratiﬁcation studies. Earlier studies
have reported on all-cause mortality, alone or in combination
with other serious events, such as cardiac death, sudden death,
or resuscitation from cardiac arrest.
9–14 Yet, it is now recognized
that many sudden cardiac deaths are not due to arrhythmia as
many other clinical conditions can evolve rapidly and result in
sudden death.
25,26 Similarly, many deaths deﬁned as non-sudden
may be due to cardiac arrhythmia.
25,26 We used an implantable
ECG-loop-recorder or other ECG recording system to document
the fatal or near-fatal arrhythmic events to be able to explore
these distinctions. Using this endpoint deﬁnition, the study gives
direct information on the performance of risk stratiﬁcation tests
to identify patients that could potentially beneﬁt from implantation
of a prophylactic ICD early after AMI. It should be noted that ICD
may not always document reliably the fatal arrhythmia because
some tachyarrhythmias may terminate spontaneously after the
pre-deﬁned delay setting of onset therapy of the devices.
27,28 In
this study, we had two such primary endpoints, where ICD termi-
nated the ventricular ﬁbrillation.
Heart rate variability and turbulence have been shown to predict
all-cause mortality and sudden cardiac death in several previous
post-AMI populations.
8,9,22,23 In recent studies, these indexes of
heart rate variability or turbulence have not been shown to be pre-
dictors of sudden death among the patients with impaired left ven-
tricular function, when measured early after the AMI.
18,23 Similarly,
a randomized ICD trial, using depressed heart rate variability and
reduced LVEF measured at an early phase after AMI, as enrolment
criteria, did not show the beneﬁt of ICD treatments on all-cause
mortality.
3 These results are partly conﬁrmed by our trial
results, where indexes of heart rate variability measured early
after AMI were not as powerful predictors of arrhythmic events
as the same parameters established 6 weeks after AMI.
Similar to previous observational studies,
11,15 QRS width from
the signal-averaged ECG predicted the occurrence of arrhythmic
................................................................................
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Table 2 Characteristics of patients at baseline (n 5 312)
Age (years) 65+11
Male gender 239 (77%)
Prior MI 116 (37%)
Prior CHF 33 (11%)
Diabetes 62 (20%)
Hypertension 136 (44%)
Blood pressure (systolic) (mmHg) 122+22
Beta-blocker
At discharge 299 (96%)
At 6 weeks after AMI 279 (89%)
ACE-inhibitor/AT blocker
At discharge 279 (89%)
At 6 weeks after AMI 260 (83%)
Statin
At discharge 256 (82%)
At 6 weeks after AMI 241 (77%)
Antiplatelet agent
At discharge 297 (95%)
At 6 weeks after AMI 274 (88%)
Characteristics of AMI
Q-wave AMI 184 (59%)
Anterior location 174 (56%)
Maximum troponin T (mmol/l) 7.0+25.5
Maximum troponin I (mmol/l) 377+644
Treatment of index MI primary PCI 45 (14%)
Thrombolysis 106 (34%)
Ejection fraction (%)
3–7 days after index MI 31+6
6 weeks after index MI 35+10
Values reported as n patients (% of population) or as mean+SD. ACE,
angiotensin converting enzyme; AMI, acute myocardial infarction; AT, angiotensin;
CHF, congestive heart failure; PCI, primary coronary intervention.
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Table 3 Arrhythmia risk variables as predictors of primary and secondary endpoints
Number of
patients
Primary endpoint: HR (95% CI),
P-value
AUC+ + + + +SD,
P-value
Overall death: HR (95% CI),
P-value
Cardiac Death: HR (95% CI),
P-value
LVEF
3–21 days after MI 312 0.97 (0.92–1.03), P ¼ 0.36 0.57+0.06, P ¼ 0.28 0.96 (0.92–1.01), P ¼ 0.09 0.96 (0.91–1.01), P ¼ 0.10
6 weeks after AMI 291 0.96 (0.92–1.01), P ¼ 0.09 0.62+0.05, P ¼ 0.07 0.97 (0.94–1.01), P ¼ 0.12 0.96 (0.92–1.01), P ¼ 0.08
Heart rate variability
SDNN
1 week 252 0.99 (0.97–1.00), P ¼ 0.07 0.65+0.07, P ¼ 0.03 0.99 (0.97–1.00), P ¼ 0.08 0.99 (0.97–1.00), P ¼ 0.09
6 weeks 239 0.98 (0.96–0.99), P ¼ 0.007 0.68+0.07, P ¼ 0.01 0.97 (0.96–0.99), P ¼ 0.002 0.97 (0.95–0.99), P ¼ 0.01
VLF spectral component
1 week 252 0.77 (0.51–1.17), P ¼ 0.22 0.59+0.08, P ¼ 0.18 0.66 (0.47–0.94), P ¼ 0.02 0.68 (0.45–1.02), P ¼ 0.06
6 weeks 239 0.44 (0.29–0.67), P , 0.001 0.73+0.07,
P ¼ 0.002
0.39 (0.26–0.58) P , 0.001 0.40 (0.24–0.66) P , 0.001
LF spectral component
1 week 251 0.98 (0.67–1.44), P ¼ 0.91 0.49+0.08, P ¼ 0.92 0.73 (0.54–0.99), P ¼ 0.04 0.71 (0.51–1.01), P ¼ 0.06
6 weeks 239 0.55 (0.37–0.82), P ¼ 0.003 0.66+0.08, P ¼ 0.03 0.47 (0.32–0.68), P , 0.001 0.49 (0.31–0.79), P ¼ 0.003
HF spectral component
1 week 251 1.21 (0.77–1.89), P ¼ 0.41 0.44+0.07, P ¼ 0.36 0.85 (0.55–1.30), P ¼ 0.44 0.79 (0.48–1.32), P ¼ 0.37
6 weeks 239 0.76 (0.44–1.30), P ¼ 0.31 0.58+0.09, P ¼ 0.28 0.55 (0.33–0.92), P ¼ 0.02 0.56 (0.29–1.05), P ¼ 0.07
Fractal scaling exponent (a1)
1 week 250 0.14 (0.03–0.62), P , 0.009 0.69+0.06,
P ¼ 0.009
0.15 (0.04–0.60), P ¼ 0.007 0.23 (0.05–1.14), P ¼ 0.07
6 weeks 236 0.06 (0.01–0.29), P , 0.001 0.75+0.06,
P ¼ 0.001
0.05 (0.01–0.60), P ¼ 0.007 0.23 (0.05–1.14), P ¼ 0.07
Heart rate turbulence
TO
1 week 243 1.08 (0.88–1.33), P ¼ 0.45 0.56+0.07, P ¼ 0.39 1.10 (0.91–1.33), P ¼ 0.31 1.09 (0.88–1.35), P ¼ 0.45
6 weeks 234 0.95 (0.80–1.13), P ¼ 0.56 0.51+0.07, P ¼ 0.92 0.95 (0.80–1.12), P ¼ 0.52 0.92 (0.75–1.12), P ¼ 0.39
TS
1 week 243 0.97 (0.90–1.04), P ¼ 0.44 0.57+0.07, P ¼ 0.31 0.97 (0.91.1.03), P ¼ 0.33 0.94 (0.85–1.03), P ¼ 0.19
6 weeks 234 0.92 (0.84–1.00), P ¼ 0.04 0.67+0.07, P ¼ 0.02 0.94 (0.87–1.01), 0.10 0.90 (0.82–1.00), P ¼ 0.05
Signal-averaged ECG
QRS width 236 1.04 (1.02–1.06), P , 0.001 0.70+0.07,
P ¼ 0.005
1.03 (1.01–1.06), P ¼ 0.004 1.04 (1.02–1.07), P , 0.001
Duration ,40 mV/ms 236 1.03 (1.00–1.05), P ¼ 0.08 0.58+0.08, P ¼ 0.24 1.03 (1.00–1.05), P ¼ 0.05 1.03 (1.00–1.07), P ¼ 0.03
rms last 40 ms 236 1.00 (0.98–1.02), P ¼ 0.88 0.56+0.09, P ¼ 0.43 0.97 (0.94–1.00), P ¼ 0.04 0.96 (0.93–1.00), P ¼ 0.07
H
.
V
.
H
u
i
k
u
r
i
e
t
a
l
.
6
9
4events, although its predictive value decreased after adjustments
with clinical variables. Induction of sustained monomorphic VT
during an electrophysiological study was also a predictor of
primary endpoint. These ﬁndings were not surprising, since both
of these risk stratiﬁcation tests describe the presence of an
electrical substrate for re-entrant ventricular tachyarrhythmias of
the infarcted myocardium increasing the vulnerability to sustained
ventricular tachycardia.
LVEF did not provide signiﬁcant additional information on the
risk of future arrhythmic events in this population. Reduced LVEF
measured early after AMI is not a speciﬁc indicator for the occur-
rence of ventricular tachyarrhythmias during the subsequent
months and this has been reported in previous prophylactic ICD
studies.
3,7 The power of this study cannot exclude the signiﬁcance
of the LVEF as predictors of serious arrhythmic events, however,
because reduced LVEF itself was an inclusion criterion resulting
in a relatively narrow range of LVEFs.
While microvolt T-wave alternans has been shown to be a risk
stratiﬁer in patients with chronic ischaemic heart failure,
29,30 the
present study did not conﬁrm its clinical beneﬁt early after the
AMI. There are a few key differences in our T-wave alternans
results compared with prior studies that deserve attention.
First, we observed a greater percentage of positive test
results,
29 because additional pacing was performed in patients
with incomplete or indeterminate test result. Secondly, prior
studies have combined incomplete and indeterminate test
results with the positives, thereby including poor exercise toler-
ance and presence of premature beats together with positive
T-wave alternans to indicate increased risk.
29,30 However, when
T-wave alternans was analysed only from exercise tests without
pacing, it did not provide prognostic information in this study,
suggesting that this test is not useful in predicting arrhythmic
events in the early post-infarction phase. Finally, concurrent
with the present study, a recent MASTER I study
31 showed
that TWA did not predict life-threatening ventricular arrhythmias
or ICD shocks in 575 post-infarction patients with depressed
LVEF.
The implantation rates of prophylactic ICD vary enormously
from one country to another in western societies.
15 The
reasons are partly economical and perhaps related to a lack of
deﬁnite scientiﬁc evidence for the clinical beneﬁts of ICDs in
different clinical settings. In particular, evidence for the beneﬁts
of prophylactic ICD among patients with a recent AMI and
reduced LVEF is sparse.
3,7 The relatively small sample size of
our study may limit the generalization of the results, yet the
data clearly suggest that indications relying exclusively on low
LVEF can further beneﬁt from additional risk stratiﬁcation tests.
Using the pre-deﬁned cut-off values of many risk variables, the
negative predictive value exceeded 95%, suggesting that these
methods could become useful in excluding the patients who
need the ICD after AMI.
The risk stratiﬁcation tests were performed relatively late after
AMI and the measures of heart rate variability predicted the
primary endpoint better when measured late than early after
AMI. Therefore, the present study does not provide information
on prediction of arrhythmia events occurring very early (,6
weeks) after AMI.
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Prediction of serious arrhythmias 695Many previous observational studies have assessed the ability of
one or two risk variables in prediction of sudden death or all-cause
mortality after AMI. This study is, as far as we know, the only
observational study comparing the predictive value of electro-
physiological testing and several non-invasive risk stratiﬁcation
tests in predicting the arrhythmic events in the same study. There-
fore, the results can be used in the design of future randomized
ICD trials of post-AMI patients. We have shown here that a
generally available, simple, and inexpensive measurement of 24 h
heart rate variability, performed 6 weeks after AMI, could
provide useful information for selecting patients who might
beneﬁt from implantation of an ICD. While the results are prom-
ising, prospective validation of this approach will be needed in
larger patient population, using randomized interventional study
design, before recommendations can be given regarding wide-
spread screening of the post-AMI patients with Holter recordings.
Figure 3 Adjusted hazard ratios (HR) with 95% conﬁdence intervals of the variables as predictors of primary endpoint. HR are calculated
from pre-deﬁned threshold values of continuous variables. HR are adjusted for age, prior myocardial infarction, history of congestive heart
failure and diabetes The variables are listed in descending order starting with the highest HR for each risk stratiﬁcation method. Abbreviations:
see in Table 3.
...............................................................................................................................................................................
Table 4 Sensitivity, speciﬁcity, and predictive accuracy of predeﬁned values of individual variables in predicting primary
endpoint
Name of variable Sensitivity (%) (95% CI) Speciﬁcity (%) (95% CI) PPV (%) (95% CI) NPV (%) (95% CI)
LVEF , 0.35 57 (36–78) 53 (47–59) 9 (4–13) 94 (90–98)
SDNN ,70 ms 35 (13–58) 90 (86–94) 21 (6–35) 95 (92–98)
VLF spectral component ln  5.7 ms
2 41 (18–65) 91 (87–95) 26 (9–42) 95 (92–98)
Fractal scaling exponent ,0.75 65 (42–87) 71 (65–77) 15 (7–23) 96 (93–99)
Heart rate turbulence slope ,2.5 ms/RRi 53 (29–77) 74 (68–80) 14 (5–22) 95 (92–99)
QRS-width on SAECG .120 ms 44 (21–67) 85 (80–90) 20 (7–32) 95 (92–98)
Induction of sustained MMVT by PES 47 (23–71) 90 (86–93) 23 (9–37) 96 (95–99)
Induction of VT/VF by PES 53 (29–77) 78 (73–83) 14 (5–22) 96 (94–99)
NPV, negative predictive value; PPV, positive predictive value. For other abbreviations see Table 3.
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